We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $11.7B
1-Year Est. Return 174.13%
This Fund
S&P 500
This Quarter Est. Return
+9.11%
1 Year Est. Return
+174.13%
3 Year Est. Return
+466.81%
5 Year Est. Return
+622.69%
10 Year Est. Return
+19,772.83%
AUM
$7.02B
AUM Growth
+$483M
Cap. Flow
+$199M
Cap. Flow %
2.83%
Top 10 Hldgs %
49.95%
Holding
78
New
10
Increased
26
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$122M
2
ZLAB icon
Zai Lab
ZLAB
+$78.9M
3
DGX icon
Quest Diagnostics
DGX
+$69.7M
4
ABT icon
Abbott
ABT
+$58.5M
5
JBIO
Jade Biosciences
JBIO
+$49.3M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$149M
2
AKRO
Akero Therapeutics
AKRO
+$88.2M
3
GMED icon
Globus Medical
GMED
+$82.3M
4
ALKS icon
Alkermes
ALKS
+$65.5M
5
ARVN icon
Arvinas
ARVN
+$23.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Financials 0.11%
3 Miscellaneous 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
1
Madrigal Pharmaceuticals
MDGL
$12.1B
$603M 8.59%
1,993,687
– –
NTRA icon
2
Natera
NTRA
$50.6B
$438M 6.24%
2,593,645
+99
+0% +$15.4K
PTCT icon
3
PTC Therapeutics
PTCT
$5.48B
$378M 5.39%
7,746,415
+263,288
+4% +$12.5M
ARGX icon
4
argenx
ARGX
$61.3B
$371M 5.29%
673,497
– –
PTGX icon
5
Protagonist Therapeutics
PTGX
$9.28B
$318M 4.53%
5,756,277
+36,862
+0.6% +$1.77M
INSM icon
6
Insmed
INSM
$26.2B
$310M 4.42%
3,084,558
+70,000
+2% +$5.35M
AKRO
7
DELISTED
Akero Therapeutics
AKRO
$292M 4.16%
5,477,561
-1,941,779
-26% -$88.2M
VRNA
8
DELISTED
Verona Pharma
VRNA
$289M 4.11%
3,051,878
+203,078
+7% +$15M
RNAM
9
DELISTED
Avidity Biosciences
RNAM
$273M 3.89%
9,618,845
+871,919
+10% +$26M
SYK icon
10
Stryker
SYK
$108B
$234M 3.33%
590,517
+296
+0.1% +$111K
PEN icon
11
Penumbra
PEN
$12.5B
$222M 3.16%
863,553
+783
+0.1% +$213K
MRUS
12
DELISTED
Merus
MRUS
$210M 3%
4,000,553
-168,840
-4% -$7.94M
ACAD icon
13
Acadia Pharmaceuticals
ACAD
$4.61B
$194M 2.76%
8,995,547
+455,430
+5% +$8.47M
ZLAB icon
14
Zai Lab
ZLAB
$2.78B
$194M 2.76%
5,536,876
+2,400,196
+77% +$78.9M
AXSM icon
15
Axsome Therapeutics
AXSM
$10.7B
$158M 2.26%
1,516,903
-1,405,826
-48% -$149M
RDNT icon
16
RadNet
RDNT
$6.07B
$153M 2.18%
2,690,344
+372,762
+16% +$20.5M
IMCR icon
17
Immunocore
IMCR
$1.64B
$153M 2.18%
4,869,798
– –
ALKS icon
18
Alkermes
ALKS
$7.72B
$134M 1.91%
4,682,289
-2,202,409
-32% -$65.5M
NBIX icon
19
Neurocrine Biosciences
NBIX
$15.2B
$133M 1.9%
+1,062,072
New +$122M
TARS icon
20
Tarsus Pharmaceuticals
TARS
$3.66B
$126M 1.8%
3,111,680
-204,352
-6% -$9.2M
APGE
21
DELISTED
Apogee Therapeutics
APGE
$118M 1.68%
2,712,097
– –
MASI
22
DELISTED
Masimo
MASI
$115M 1.64%
683,294
– –
ESTA icon
23
Establishment Labs
ESTA
$2.13B
$110M 1.57%
2,584,131
+244
+0% +$8.51K
ISRG icon
24
Intuitive Surgical
ISRG
$133B
$110M 1.57%
202,456
– –
CYTK icon
25
Cytokinetics
CYTK
$9.64B
$89.9M 1.28%
2,721,158
– –
1
2 3 4

Similar funds

CIM
Centersquare Investment Management Conshohocken, Pennsylvania $11.7B AUM 20.39% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
UE
Unisphere Establishment Vaduz, Liechtenstein $11.7B AUM 0.31% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $11.8B AUM 25.68% 1-Year Est. Return
CCMT
CMT Capital Markets Trading Frankfurt, Germany $11.8B AUM 39.43% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

RTW Investments's Q2 2025 Portfolio in Review

As of Q2 2025, RTW Investments held 78 positions worth $7.02B, up 7.4% from $6.54B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

RTW Investments's Q2 2025 filing shows 10 new, 26 increased, 8 reduced and 5 closed positions. Its largest new stake was Neurocrine Biosciences: 1,062,072 shares worth $133M. The largest sale was Axsome Therapeutics, an estimated $149M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials and Miscellaneous.

  • RTW Investments's largest Q2 2025 buy was Neurocrine Biosciences: 1,062,072 shares worth $133M.
  • RTW Investments added most to Zai Lab in Q2 2025, an estimated $78.9M increase.
  • RTW Investments's biggest Q2 2025 reduction was Axsome Therapeutics, cutting an estimated $149M.
  • RTW Investments fully exited Globus Medical in Q2 2025, selling an estimated $82.3M.
  • RTW Investments's ten largest holdings make up 50% of its $7.02B portfolio in Q2 2025.
  • RTW Investments opened 10 new positions and closed 5 in Q2 2025.
  • RTW Investments's portfolio value rose 7.4% quarter-over-quarter to $7.02B.

Based on RTW Investments's 13F filing for Q2 2025, filed 14 Aug 2025.